Literature DB >> 33323025

Pro-Inflammatory Interleukin-18 is Associated with Hepatic Steatosis and Elevated Liver Enzymes in People with HIV Monoinfection.

Jae H Sim1, Julia B Sherman1, Takara L Stanley1, Kathleen E Corey2, Kathleen V Fitch1, Sara E Looby1, Jake A Robinson3, Michael T Lu4, Tricia H Burdo3, Janet Lo1.   

Abstract

People with HIV (PWH) are at an increased risk of developing nonalcoholic fatty liver disease (NAFLD). Interleukin (IL)-18 is regulated by inflammasomes in response to pathogens and danger signals and has been implicated in both the pathogenesis of NAFLD and HIV disease progression. We hypothesized that increased IL-18 may be associated with NAFLD and liver injury in PWH. This was an observational study of 125 PWH and 59 individuals without HIV in the Boston area. Participants with known hepatitis B, hepatitis C, and excessive alcohol use were excluded. IL-18 was measured in serum by enzyme-linked immunosorbent assay. Liver lipid content was assessed by liver-to-spleen computed tomography (CT) attenuation ratio. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and IL-18 levels were higher in PWH than in controls. In PWH, log10 IL-18 was associated with log10AST (r = 0.34, p = .0001), log10ALT (r = 0.33, p = .0002), log10HIV RNA (r = 0.29, p = .002), and inversely associated with liver-to-spleen ratio (r = -0.24, p = .02). In addition, log10 IL-18 was associated with log10 triglycerides (r = 0.26, p = .003), log10 MCP-1 (monocyte chemoattractant protein-1; r = 0.33, p = .0004), log10caspase-1 (r = 0.35, p < .0001), log10LPS (r = 0.28, p = .004), and inversely associated with high-density lipoprotein (r = -0.28, p = .002), and CD4+/CD8+ T cell ratio (r = -0.24, p = .007). In controls without HIV, log10 IL-18 was also associated with log10ALT (r = 0.44, p = .0005). After adjusting for potential confounders, the relationships between IL-18 and AST (p = .004) and ALT (p = .003) remained significant, and the relationship between IL-18 and liver-to-spleen ratio (p = .02). Increased inflammasome activation and subsequent monocyte recruitment in PWH may contribute to the development and progression of NAFLD. Clinical Trials Registration. NCT00455793.

Entities:  

Keywords:  NAFLD; NASH; inflammasome; interleukin-18

Mesh:

Substances:

Year:  2021        PMID: 33323025      PMCID: PMC8112718          DOI: 10.1089/AID.2020.0177

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  28 in total

1.  NLRP3 inflammasome activation is required for fibrosis development in NAFLD.

Authors:  Alexander Wree; Matthew D McGeough; Carla A Peña; Martin Schlattjan; Hongying Li; Maria Eugenia Inzaugarat; Karen Messer; Ali Canbay; Hal M Hoffman; Ariel E Feldstein
Journal:  J Mol Med (Berl)       Date:  2014-05-28       Impact factor: 4.599

2.  Elevated levels of circulating interleukin-18 in human immunodeficiency virus-infected individuals: role of peripheral blood mononuclear cells and implications for AIDS pathogenesis.

Authors:  Rasheed Ahmad; Sardar T A Sindhu; Emil Toma; Richard Morisset; Ali Ahmad
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  Weight loss reduces interleukin-18 levels in obese women.

Authors:  Katherine Esposito; Alessandro Pontillo; Myriam Ciotola; Carmen Di Palo; Elisa Grella; Gianfranco Nicoletti; Dario Giugliano
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

4.  Noncalcified coronary atherosclerotic plaque and immune activation in HIV-infected women.

Authors:  Kathleen V Fitch; Suman Srinivasa; Suhny Abbara; Tricia H Burdo; Kenneth C Williams; Peace Eneh; Janet Lo; Steven K Grinspoon
Journal:  J Infect Dis       Date:  2013-09-16       Impact factor: 5.226

5.  Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study.

Authors:  I Vodkin; M A Valasek; R Bettencourt; E Cachay; R Loomba
Journal:  Aliment Pharmacol Ther       Date:  2014-12-11       Impact factor: 8.171

6.  Interleukin 18 stimulates HIV type 1 in monocytic cells.

Authors:  L Shapiro; A J Puren; H A Barton; D Novick; R L Peskind; R Shenkar; Y Gu; M S Su; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

Review 7.  Inflammasome activation and function in liver disease.

Authors:  Gyongyi Szabo; Jan Petrasek
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-06-09       Impact factor: 46.802

8.  NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.

Authors:  Auvro R Mridha; Alexander Wree; Avril A B Robertson; Matthew M Yeh; Casey D Johnson; Derrick M Van Rooyen; Fahrettin Haczeyni; Narci C-H Teoh; Christopher Savard; George N Ioannou; Seth L Masters; Kate Schroder; Matthew A Cooper; Ariel E Feldstein; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2017-02-03       Impact factor: 25.083

9.  A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Authors:  Scott L Friedman; Vlad Ratziu; Stephen A Harrison; Manal F Abdelmalek; Guruprasad P Aithal; Juan Caballeria; Sven Francque; Geoffrey Farrell; Kris V Kowdley; Antonio Craxi; Krzysztof Simon; Laurent Fischer; Liza Melchor-Khan; Jeffrey Vest; Brian L Wiens; Pamela Vig; Star Seyedkazemi; Zachary Goodman; Vincent Wai-Sun Wong; Rohit Loomba; Frank Tacke; Arun Sanyal; Eric Lefebvre
Journal:  Hepatology       Date:  2018-01-29       Impact factor: 17.425

Review 10.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Detlef Schuppan; Henning Grønbæk; Konstantin Kazankov; Simon Mark Dahl Jørgensen; Karen Louise Thomsen; Holger Jon Møller; Hendrik Vilstrup; Jacob George
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-03       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.